At the AACR Annual Meeting 2026, National Cancer Institute Director Anthony Letai offered insights into what NCI considers to...
An AACR Patient Advocate Forum assembled a panel of experts to discuss how AI tools can help advance cancer...
In April 2026, AACR's journals editors highlighted studies on cancer survivors taking GLP-1 agonists, an immunotherapy-boosting bacteria, and more.
Patient advocates from the AACR Scientist↔Survivor Program shared their research on cancer during the AACR Annual Meeting 2026.
A recap of the last day of the AACR Annual Meeting 2026, including plenaries on innovative treatment modalities and...
Injecting immunotherapy directly into precancerous oral lesions may be an effective way to prevent progression to cancer without surgery.
A recap from the fifth day of the AACR Annual Meeting 2026, including a plenary on early-onset cancers, clinical...
People with alveolar soft part sarcoma can receive immunotherapy treatment for an extended period without long-term side effects.
A recap of the fourth day of the AACR Annual Meeting 2026, including a plenary on AI, the NCI...
A recap from the third day of the AACR Annual Meeting 2026, including the Opening Plenary, Clinical Trial Plenaries,...
A recap from the second day of the AACR Annual Meeting 2026, including the 5K, clinical trials, Discovery Science...